Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin.

ABSTRACT:

Background

SGLT2 (sodium/glucose cotransporter 2) inhibitors exert robust cardioprotective effects against heart failure in patients with diabetes, and there is intense interest to identify the underlying molecular mechanisms that afford this protection. Because the induction of the late component of the cardiac sodium channel current (late-I_Na) is involved in the etiology of heart failure, we investigated whether these drugs inhibit late-I_Na.

Methods

Electrophysiological, in silico molecular docking, molecular, calcium imaging, and whole heart perfusion techniques were used to address this question.

Results

The SGLT2 inhibitor empagliflozin reduced late-I_Na in cardiomyocytes from mice with heart failure and in car

SUBMITTER: Philippaert K 

PROVIDER: S-EPMC8154177 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature